1. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35:802-812.

2. Wallace EL, Churchill WH, Surgenor DM, Cho GS, McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998; 38:625-636.

3. National Blood Data Resource Center. Comprehensive Report on Blood Collection and Transfusion in the United States in 2001. Bethesda, MD: National Blood Data Resource Center. 2003.

4. Pall Corp. Demand leukocyte-depleted blood for more complete patient protection. Ann Thorac Surg 1997; 60:A20-A21.

5. Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitzngel E. Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vox Sang 1999; 77:24-32.

6. Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine, first of two parts— blood transfusion. N Engl J Med 1999; 340:438-447.

7. Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982-1991. Transfusion 1993; 33:890-893.

8. Dodd RY, Notari ED, Stramer SL. Current prevalence and incidence of infectious markers and estimated window-period risk in the American Red Cross donor population. Transfusion 2002; 42:975-979.

9. Stevens CE, Aach RD, Hollinger FB, et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med 1984; 101:733-738.

10. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A and non-B hepatitis. N Engl J Med 1989; 321:1494-1500.

11. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-35.

12. Corash L, Behrman B, Rheinschmidt M, et al. Post-transfusion viability and tolerability of photochem-ically treated platelet concentrates. Blood 1997; 90:267a.

13. McCullough J, Vesole D, Benjamin RJ, Slichter S, Pineda A, Snyder E, et al. Pathogen-inactivated platelets using Helinx™ Technology are hemostatically effective in the thrombocytopenia patient. Blood 2001; 98:45A.

14. Sayers MH, Anderson KC, Goodnough LT, et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992; 116:55-62.

15. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte reduced and cytomegalovirus (CMV)-seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86:3598-3603.

16. Rubie H, Attal M, Campardou AM, et al. Risk factors for cytomegalovirus in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 1993; 11:209-214.

17. Vij R, Adkins D, Brown R, et al. Risk factors for cytomegalovirus (CMV) viremia post related donor allogeneic peripheral blood stem cell transplantation. Blood 1999; 94:374b.

18. Wingard JR, Sostrin MB, Vriessendorp HM, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46:61-65.

19. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94:4029-4035.

20. Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of leukoreduc-tion: a consensus statement. Transfusion 2001; 41:560-569.

21. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood 1996; 87:4910.

22. Goodnough LT. The case against universal WBC (and for the practice of evidence-based medicine). Transfusion 2000; 40:1522-1527.

23. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992; 117:151-162.

24. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what blood component should be given next? Vox Sang 1982; 42:318-321.

25. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861-1869.

26. Goodnough LT, Riddell J, Lazarus H, et al. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993; 65:103-107.

27. Uhlman EJ, Isriggs E, Walhermfechtel M, Goodnough LT. Pre-storage universal WBC of RBC units does not affect the incidence of transfusion reactions. Ttransfusion 2001; 41:997-1000.

28. Dzik WH, Anderson JK, O Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized trial of universal WBC reduction. Transfusion 2002; 42:1114-1122.

29. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39:665-670.

30. Ober C, Karrison T, Odem RR, et. al. Mononuclear-cell immunization in prevention of recurrent miscarriages: a randomized trial. Lancet 1999; 354:365-369.

31. Opelz G, Terasaki PI: Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978; 299:799-803.

32. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36:175-186.

33. Bernstein SH, Nadermanee AP, Vose JM, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91:3509-3517.

34. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337:1870-1875.

35. Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:3601-3606.

36. Menitove JE, ed. Standards for Blood Banks and Transfusion Services. Bethesda, MD: American Association of Blood Banks. 1999.

37. Goodnough LT, Ali S, Despotis GJ, Dynis M, DiPersio JF. Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy. Vox Sang 1999; 76:43-49.

38. Hersh JK, Hom EG, Brecher ME. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronic platelet transfusion dependent patient. Transfusion 1998; 38:637-644.

39. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for fixed platelet requirements. Blood 1985; 66:1105-1109.

40. Klumpp TR, Herman JH, Gaughan JP, et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized double-blind trial. Transfusion 1999; 39:674-681.

41. Norol F, Bierling P, Roudot-Throvac F, et al. Platelet transfusion: a dose-response study. Blood 1998; 92:1448-1453.

42. Ishida A, Handa M, Wakui M, Okamota S, Kamakuva M, Ikeda Y. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic pregenitor cell transplantation—a prospective analysis. Transfusion 1998; 38:839-847.

43. Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D. Thrombopoiesis and Thrombopoietins. Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, NJ: Humana. 1997.

44. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457-3469.

45. Paul SR, Bennett F, Calvetti JA, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87:7512-7516.

46. Yin TG, Schendel P, Yang YC. Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med 1992; 175:211-216.

47. Burnstein SA, Mei RL, Hentthron J, Friese P, Turner K. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 1992; 153:305-312.

48. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992; 79:327-331.

49. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human inter-leukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87:3615-3624.

50. Vredenburgh JJ, Hussein A, Fisher D, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant 1998; 4:134-141.

51. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant human inter-leukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87:3607-3614.

52. Hokom MM, Lacey D, Kinstler O, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86:4486-4492.

53. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348:1279-1281.

54. Basser RL, Rasko JEJ, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after doseintensive chemotherapy in patients with advanced cancer. Blood 1997; 89:3118-3128.

55. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336:404-409.

0 0

Post a comment